medigraphic.com
SPANISH

Acta Médica Grupo Angeles

Órgano Oficial del Hospital Angeles Health System
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
    • Names and affiliations of the Editorial Board
  • Policies
  • About us
    • Data sharing policy
    • Stated aims and scope
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2011, Number 2

<< Back Next >>

Acta Med 2011; 9 (2)

Churg-Strauss syndrome associated to pranlukast treatment

Ángeles-Labra AR, Shturman-Ellstein R, Díaz-Borjón A
Full text How to cite this article

Language: Spanish
References: 7
Page: 100-102
PDF size: 241.43 Kb.


Key words:

Churg-Strauss’ syndrome, pranlukast.

ABSTRACT

The Churg-Strauss syndrome (CSS) is a rare vasculitis of small and medium caliber vessels, which occurs in patients with a history of asthma and atopy. The leukotriene receptor antagonists currently have an important role in asthma control and facilitate the reduction of steroid dosage. We report a case of a 43-year-old woman with a history of atopy, sinusitis and asthma diagnosed at 41 years, treated with pranlukast to taper the prednisone dose. The patient subsequently presented non-productive cough, chest pain, malaise and fever up to 38.5 °C, and had no response to antibiotic treatment. Screening studies showed multiple foci pneumonia, eosinophilia, ESR, CRP, and elevated serum IgE. Lung biopsy specimen showed eosinophilic infiltration through the vascular wall, compatible with CSS. Some reports in the literature have suggested a causal relationship between leukotriene receptor antagonists and this syndrome, however this association is controversial. It is unknown if there is a direct induction role of pranlukast for the development of the disease, or if the latter is unmasked by reducing use of systemic corticosteroids.


REFERENCES

  1. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol 1951; 27: 277-301.

  2. Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, Polito AJ et al. Pulmonary infiltrates, eosinophilia and cardiomiopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279: 455-457.

  3. Nathani N, Little M, Kunst H, Wilson D, Thickett D. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63: 883-888.

  4. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al. The American Rheumatology criteria 1990 for the classification of Churg-Strauss syndrome. Arthritis Rheum 1990; 33: 1094.

  5. Noth I, Strek ME, Leff AR. Churg Strauss syndrome. Seminar Lancet 2003; 361: 587-94.

  6. Weller PF, Plant M, Taggart V, Trentell A. The relationship of asthma therapy and Churg-Strauss Syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108: 175-83.

  7. Barnes NC, Pujet JC. Pranlukast a novel leucotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52: 523-527.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med. 2011;9